ATE353328T1 - Adenosin rezeptor antagonisten sowie methoden zu deren herstellung und verwendung - Google Patents

Adenosin rezeptor antagonisten sowie methoden zu deren herstellung und verwendung

Info

Publication number
ATE353328T1
ATE353328T1 AT00983698T AT00983698T ATE353328T1 AT E353328 T1 ATE353328 T1 AT E353328T1 AT 00983698 T AT00983698 T AT 00983698T AT 00983698 T AT00983698 T AT 00983698T AT E353328 T1 ATE353328 T1 AT E353328T1
Authority
AT
Austria
Prior art keywords
production
methods
receptor antagonists
adenosine receptor
adenosine
Prior art date
Application number
AT00983698T
Other languages
English (en)
Inventor
James E Dowling
Carol Ensinger
Gnanasambandam Kumaravel
Russell C Petter
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of ATE353328T1 publication Critical patent/ATE353328T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT00983698T 1999-11-12 2000-11-13 Adenosin rezeptor antagonisten sowie methoden zu deren herstellung und verwendung ATE353328T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16528399P 1999-11-12 1999-11-12

Publications (1)

Publication Number Publication Date
ATE353328T1 true ATE353328T1 (de) 2007-02-15

Family

ID=22598257

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00983698T ATE353328T1 (de) 1999-11-12 2000-11-13 Adenosin rezeptor antagonisten sowie methoden zu deren herstellung und verwendung

Country Status (33)

Country Link
US (4) US6605600B1 (de)
EP (2) EP1230241B1 (de)
JP (1) JP2003513976A (de)
KR (1) KR100845488B1 (de)
CN (1) CN1187354C (de)
AT (1) ATE353328T1 (de)
AU (1) AU784528B2 (de)
BG (1) BG106693A (de)
BR (1) BR0015540A (de)
CA (1) CA2390590C (de)
CY (1) CY1106560T1 (de)
CZ (1) CZ20021615A3 (de)
DE (1) DE60033310T2 (de)
DK (1) DK1230241T3 (de)
EA (1) EA010260B1 (de)
EE (1) EE200200248A (de)
ES (1) ES2281367T3 (de)
GE (1) GEP20043267B (de)
HK (1) HK1049153B (de)
HU (1) HUP0203371A3 (de)
IL (1) IL149486A0 (de)
IS (1) IS6380A (de)
MX (1) MXPA02004795A (de)
NO (1) NO20022237L (de)
NZ (2) NZ519427A (de)
PL (1) PL198156B1 (de)
PT (1) PT1230241E (de)
SK (1) SK6622002A3 (de)
TR (1) TR200301062T2 (de)
UA (1) UA77937C2 (de)
WO (1) WO2001034604A2 (de)
YU (1) YU33702A (de)
ZA (1) ZA200203702B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
EP2305684A1 (de) * 1999-11-12 2011-04-06 Biogen Idec MA Inc. Polycycloalkylpurine als Adenosinrezeptorantagonisten
CA2390590C (en) * 1999-11-12 2010-03-16 Biogen, Inc. Adenosine receptor antagonists and methods of making and using the same
UA84404C2 (ru) * 2002-06-12 2008-10-27 Байоджен Айдек Ма Инк. Способ лечения ишемического реперфузионного повреждения с помощью антагонистов рецептора аденозина
WO2004009594A2 (en) * 2002-07-19 2004-01-29 Aryx Therapeutics Xanthine derivatives having adenosine a1-receptor antagonist properties
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
MXPA05011070A (es) * 2003-04-14 2005-12-12 Pfizer Prod Inc Derivados de 3-azabiciclo [3.2.1] octano.
EP1620107A1 (de) * 2003-04-25 2006-02-01 Novacardia, Inc. Methode zur verbesserung der diurese bei patienten mit eingeschränkter nierenfunktion
EP1636229A4 (de) * 2003-06-06 2008-07-30 Endacea Inc A1-adenosinrezeptorantagonisten
US20070208040A1 (en) * 2006-03-02 2007-09-06 Elfatih Elzein A2a adenosine receptor antagonists
CA2648281A1 (en) * 2006-04-06 2007-10-18 Novacardia, Inc. Co-administration of adenosine a1 receptor antagonists and anticonvulsants
US7872017B2 (en) 2006-05-19 2011-01-18 Abbott Laboratories Fused bicycloheterocycle substituted azabicyclic alkane derivatives
JP2009540003A (ja) * 2006-06-16 2009-11-19 ノヴァカーディア，インク． Ａａ１ｒａの低頻度投与を含む腎機能の長期間にわたる改善
WO2008121882A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Improved methods of administration of adenosine a1 receptor antagonists
WO2008121893A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
US20090228097A1 (en) * 2008-03-07 2009-09-10 Abbott Cardiovascular Systems Inc. A1 Adenosine Receptor Antagonist-Coated Implantable Medical Device
CN114790164B (zh) 2021-08-13 2022-12-27 苏州璞正医药有限公司 一种取代的异吲哚啉-1,3-二酮类pde4抑制剂及其药物用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155664A (en) * 1959-11-13 1964-11-03 Endo Lab Derivatives of theophylline
DE8817122U1 (de) 1988-12-22 1993-02-04 Boehringer Ingelheim Kg, 55218 Ingelheim Neue Xanthinderivate mit Adenosinantogenistischer Wirkung
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
US5290782A (en) 1989-09-01 1994-03-01 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
EP0423805B1 (de) 1989-10-20 2000-08-23 Kyowa Hakko Kogyo Kabushiki Kaisha Kondensierte Purinderivate
DE4019892A1 (de) 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
CA2061544A1 (en) 1991-02-25 1992-08-26 Fumio Suzuki Xanthine compounds
CA2082325A1 (en) 1991-11-08 1993-05-09 Fumio Suzuki Xanthine derivatives
JPH05294966A (ja) 1992-02-17 1993-11-09 Kyowa Hakko Kogyo Co Ltd キサンチン誘導体
US5342841A (en) 1992-03-12 1994-08-30 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
TW252044B (de) 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
WO1994016702A1 (fr) 1993-01-26 1994-08-04 Kyowa Hakko Kogyo Co., Ltd. Medicament contre l'elimination irreguliere des matieres fecales
JP3729874B2 (ja) * 1993-04-07 2005-12-21 協和醗酵工業株式会社 キサンチン誘導体
US5395836A (en) 1993-04-07 1995-03-07 Kyowa Hakko Kogyo Co., Ltd. 8-tricycloalkyl xanthine derivatives
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
AU7675498A (en) 1997-06-16 1999-01-04 Kyowa Hakko Kogyo Co. Ltd. Preventive and remedy for drug-induced nephropathy
WO1998057645A1 (en) 1997-06-16 1998-12-23 Kyowa Hakko Kogyo Co., Ltd. Hepatic edema remedy
DE19816857A1 (de) 1998-04-16 1999-10-21 Boehringer Ingelheim Pharma Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP0955301A3 (de) * 1998-04-27 2001-04-18 Pfizer Products Inc. 7-Aza-bicyclo[2.2.1]-heptan Derivate, deren Herstellung und Verwendung aufgrund ihrer Affinität für neuronale nikotinische Acetylcholin Rezeptoren
AU4396899A (en) 1998-07-02 2000-01-24 Kyowa Hakko Kogyo Co. Ltd. Remedies for diabetes
CA2390590C (en) * 1999-11-12 2010-03-16 Biogen, Inc. Adenosine receptor antagonists and methods of making and using the same
EP2305684A1 (de) * 1999-11-12 2011-04-06 Biogen Idec MA Inc. Polycycloalkylpurine als Adenosinrezeptorantagonisten

Also Published As

Publication number Publication date
EP1230241A2 (de) 2002-08-14
US20030225038A1 (en) 2003-12-04
GEP20043267B (en) 2004-06-25
MXPA02004795A (es) 2005-07-01
DE60033310D1 (de) 2007-03-22
EP1775297A3 (de) 2008-12-03
BR0015540A (pt) 2002-07-23
TR200301062T2 (tr) 2003-09-22
UA77937C2 (en) 2007-02-15
DE60033310T2 (de) 2007-11-22
EP1775297A2 (de) 2007-04-18
WO2001034604A2 (en) 2001-05-17
HK1049153B (en) 2007-09-28
AU2042101A (en) 2001-06-06
YU33702A (sh) 2005-03-15
US6605600B1 (en) 2003-08-12
EP1230241B1 (de) 2007-02-07
EA200200562A1 (ru) 2002-10-31
ZA200203702B (en) 2003-10-29
US20080004293A1 (en) 2008-01-03
US20050222179A1 (en) 2005-10-06
JP2003513976A (ja) 2003-04-15
HUP0203371A2 (hu) 2003-02-28
AU784528B2 (en) 2006-04-27
EA010260B1 (ru) 2008-06-30
NZ519427A (en) 2003-08-29
HUP0203371A3 (en) 2005-02-28
NO20022237D0 (no) 2002-05-10
HK1049153A1 (en) 2003-05-02
KR100845488B1 (ko) 2008-07-10
CA2390590A1 (en) 2001-05-17
ES2281367T3 (es) 2007-10-01
IL149486A0 (en) 2002-11-10
PL356044A1 (en) 2004-06-14
CY1106560T1 (el) 2012-01-25
CN1399636A (zh) 2003-02-26
DK1230241T3 (da) 2007-06-04
PL198156B1 (pl) 2008-05-30
NZ527918A (en) 2005-05-27
WO2001034604A3 (en) 2002-01-10
CZ20021615A3 (cs) 2002-08-14
EE200200248A (et) 2003-06-16
IS6380A (is) 2002-05-10
PT1230241E (pt) 2007-05-31
KR20020049043A (ko) 2002-06-24
CN1187354C (zh) 2005-02-02
NO20022237L (no) 2002-07-12
BG106693A (bg) 2003-01-31
SK6622002A3 (en) 2003-02-04
CA2390590C (en) 2010-03-16

Similar Documents

Publication Publication Date Title
CY1110512T1 (el) Πολυκυκλοαλκυλοπουρινες ως ανταγωνιστες υποδοχεων αδενοσινης
ATE353328T1 (de) Adenosin rezeptor antagonisten sowie methoden zu deren herstellung und verwendung
WO1997020823A3 (en) 2-amino quinazoline derivatives as npy receptor antagonists
NO920945L (no) Nye 8-substituerte puriner som selektive adenosinreseptormidler
CA2275686A1 (en) Isoquinolinamine and phthalazinamine derivatives which interact with crf receptors
NZ533358A (en) 3,4-Dihydro-1H-isoquinolin-2-yl-derivatives for use as NK2 receptor antagonists
ATE398614T1 (de) Triazolverbindungen und ihre therapeutische verwendung
NO20053612L (no) 1,2,4-triaminobenzenderivater nyttige for behandling av forstyrrelser i sentralnervesystemet

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1230241

Country of ref document: EP